

Amendments to the Claims

1-69. (canceled)

70. (new) A method of treating or preventing a vascular disease of a patient with a plurality of stent preforms interlaced to form a stent, the method comprising:

examining vessel walls of said patient for presence of a proliferation of smooth muscle cells having a spindle shape;

selecting a combination of therapeutic agents that acts to decrease proliferation of said smooth muscle cells having a spindle shape, the plurality of stent preforms including the therapeutic agents; and

implanting the stent in the patient to treat or prevent the vascular disease, wherein each of the plurality of stent preforms comprises:

an elongated metallic core including a contact surface and first and second ends;

an outer sheath disposed about the contact surface of the core, the outer sheath including the therapeutic agents; and

caps disposed on the ends of the outer sheath thereby encapsulating the first and second ends of the core.

71. (new) The method of claim 70, wherein said combination of therapeutic agents is cyclosporine A and sirolimus (rapamycin), imatinib mesylate and sirolimus (rapamycin), or curcumin and sirolimus (rapamycin).

72. (new) The method of claim 70, wherein said combination of therapeutic agents is disposed within pores of the outer sheath.

73. (new) The method of claim 70, wherein the core is formed of shape-memory alloy.

74. (new) The method of claim 70, wherein the outer sheath is formed of a polymeric material.
75. (new) The method of claim 74, wherein the polymeric material is biostable.
76. (new) The method of claim 70, further comprising a release mechanism disposed over the outer sheath.
77. (new) The method of claim 76, wherein the release mechanism is a bioabsorbable polymer.
78. (new) The method of claim 70, wherein said combination of therapeutic agents is coated on the outer sheath.
79. (new) The method of claim 78, wherein a release mechanism is disposed over said combination of therapeutic agents.